Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07545226 · ClinicalTrials.gov registry record · Phase 1
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.
A Phase 1 study, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 400
- Enrollment target
NCT07545226: Recruiting Phase 1 study, sponsored by Amgen.
NCT07545226 is a Phase 1 study that is actively recruiting participants, run by Amgen. The registered enrollment target is 400 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (567% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07545226, a Phase 1 study, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 400 participants
- Enrollment target
Study Summary
The primary objective of this trial is to evaluate the pharmacokinetics (PK) of two evolocumab drug products in healthy participants.
Interventions
- DRUG Evolocumab Drug Substance A (Test)
- DRUG Evolocumab Drug Substance B (Reference)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2026-04-21 |
| Est. Completion | 2026-09-08 |
| Phase | Phase 1 |
What NCT07545226 shows while recruiting
NCT07545226 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (567% higher).
The record links to 0 conditions, and to 2 interventions - of which Evolocumab Drug Substance A (Test) is the first listed.
NCT07545226 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07545226 about?
NCT07545226 is a clinical study titled "Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.". The primary objective of this trial is to evaluate the pharmacokinetics (PK) of two evolocumab drug products in healthy participants.
What is the current status of trial NCT07545226?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 400 participants. The study started on 2026-04-21. Estimated completion is 2026-09-08.
What interventions are being tested in trial NCT07545226?
The interventions under investigation include: Evolocumab Drug Substance A (Test) (DRUG), Evolocumab Drug Substance B (Reference) (DRUG).
Who is sponsoring clinical trial NCT07545226?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07545226's enrollment target sits among peer trials
400 75th of 2000 higher than 1,924 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI